Facon T, et al. - Given that lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation, researchers ascertained if the addition of daratumumab would significantly lessen the risk of disease progression or death in this population. For this investigation,737 patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation were randomly assigned to receive daratumumab plus lenalidomide and dexamethasone (daratumumab group) or lenalidomide and dexamethasone alone (control group). The risk of disease progression or death was significantly lower among those who received daratumumab plus lenalidomide and dexamethasone than among those who received lenalidomide and dexamethasone alone among newly diagnosed patients with multiple myeloma who were not eligible for autologous stem cell transplantation. In the daratumumab group, there was a higher incidence of neutropenia and pneumonia.